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Abstract
Cyclosporine A (CSA) is a type 2B phosphatase inhibitor which can induce contraction of renal artery smooth muscle. In
this investigation, we examined the phosphorylation events associated with CSA-induced contraction of bovine renal artery
smooth muscle. Contractile responses were determined in a muscle bath and the corresponding phosphorylation events were
determined with whole cell phosphorylation and two-dimensional gel electrophoresis. CSA-induced contractions were
associated with increases in the phosphorylation of the 20 kDa myosin light chains (MLC20) and different isoforms of the
small heat shock protein, HSP27. Cyclic nucleotide-dependent relaxation of CSA-induced contractions was associated with
increases in the phosphorylation of another small heat shock protein, HSP20, and decreases in the phosphorylation of the
MLC20, and some isoforms of HSP27. These data suggest that CSA-induced contraction and relaxation of vascular smooth
muscle is associated with increases in the phosphorylation of specific contractile regulatory proteins. ß 1999 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Cyclosporine A (CSA) is an immunosuppressant
drug used for the prevention of graft rejection after
transplantation. The clinical usefulness of CSA is
limited by vascular toxicity, which is manifest by
systemic hypertension and nephrotoxicity [1,2].
CSA therapy leads to an increase in renal vascular
resistance and a decrease in renal blood £ow in hu-
mans and in animal models [3,4]. It has been pro-
posed that CSA decreases renal blood £ow by induc-
ing the release of vasoconstrictor substances,
decreasing the endothelial production of vasorelax-
ants, or by a direct e¡ect on the vascular smooth
muscle [5^8]. The e¡ects of CSA on the vascular
smooth muscle include enhanced responsiveness to
vasoconstrictors, decreased responsiveness to vasore-
laxants, and a direct contractile e¡ect on rat aortic
and bovine renal smooth muscle [6,8^11].
The proposed mechanism of action of CSA as an
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immunosuppressant is via binding to the intracellular
cyclophilins and inactivating the Ca2- and calmodu-
lin-dependent protein phosphatase (type 2B phos-
phatase otherwise known as calcineurin) in T-lym-
phocytes [12]. Since other phosphatase inhibitors,
such as okadaic acid and calyculin, are potent medi-
ators of vascular smooth muscle contraction [13,14],
we hypothesized that CSA-induced vascular smooth
muscle contractions would be associated with in-
creases in the phosphorylation of speci¢c contractile
regulatory proteins.
2. Materials and methods
2.1. Materials
CSA was from Sandoz (East Hanover, NJ);
[32P]orthophosphate from Amersham (Arlington
Heights, IL); N-2-hydroxyethylpiperazine-NP-2-eth-
anesulfonic acid (HEPES), ethylene glycol-bis(L-ami-
no ethyl ether) N,N,NP,NP-tetraacetic acid (EGTA),
ethylenediaminetetraacetic acid (EDTA), (3-[(3-chol-
amidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS), cremophore, and all other analytical grade
chemicals were from Sigma (St. Louis, MO). Mouse
monoclonal anti-HSP27 antibodies were from Dr.
M.J. Welsh (University of Michigan, Ann Arbor,
MI) [15] and rabbit polyclonal anti-MLC20 antibod-
ies were from Dr. J. Stull (University of Texas, Dal-
las, TX). Goat anti-mouse secondary antibodies were
from Jackson Immunochemical (West Grove, PA).
Electrophoresis reagents and the DC protein assay
kit were from Bio-Rad (Hercules, CA).
2.2. Muscle bath experiments
Bovine renal arteries were obtained from an abat-
toir and placed directly in cold HEPES bu¡er (140
mM NaCl, 4.7 mM KCl, 1.0 mM MgSO4, 1.0 mM
NaH2PO4, 1.5 mM CaCl2, 10 mM glucose, and 10
mM HEPES, pH 7.4). The vessels were opened lon-
gitudinally and the adventitia was dissected free of
the vessel. The endothelium was removed by rubbing
the strip with a cotton tipped applicator. Transverse
strips, 1.0 mM in diameter, were cut, and a loop of
3-0 silk was tied to each end. The strips were sus-
pended in a muscle bath containing bicarbonate bu¡-
er (120 mM NaCl, 4.7 mM KCl, 1.0 mM MgSO4,
1.0 mM NaH2PO4, 10 mM glucose, 1.5 mM CaCl2,
and 25 mM Na2HCO3, pH 7.4), equilibrated with
95% O2/5% CO2, at 37‡C for at least 1 h. Changes
in isometric force were registered by tension trans-
ducers (Grass, Quincy, MA) and recorded on a chart
recorder (Gould, Norcross, GA). The strips were
progressively stretched and the isometric force gen-
erated in response to 110 mM KCl (made with equi-
molar replacement of NaCl in bicarbonate bu¡er)
was determined until optimal tension was produced.
CSA and forskolin were solubilized in DMSO and
then added directly to the muscle bath at dilutions
greater than 1/100. DMSO, 1/100 dilution, had no
e¡ect on smooth muscle contractile responses (data
not shown).
2.3. Whole cell phosphorylation and two-dimensional
gel electrophoresis
Strips of renal artery smooth muscle were equili-
brated in bicarbonate bu¡er bubbled with 95% O2/
5% CO2 for 1 h at 37‡C. The strips were then rinsed
and incubated in low-phosphate bu¡er (10 mM
HEPES pH 7.4, 140 mM NaCl, 4.7 mM KCl, 1.0
mM MgCl2, 1.5 mM CaCl2, 10 mM glucose, and
0.3 mM NaH2PO4) for 30 min. The strips were
then equilibrated in low-phosphate bu¡er containing
250 WCi/ml [32P]orthophosphate for 1 h. The strips
were treated with CSA (0.4 mM for 10 min) or re-
mained in bu¡er as controls. The doses of CSA used
in this study were the half-maximal dose of CSA
required for contraction of bovine renal artery
smooth muscle in vitro [11]. The incubation was ter-
minated by immersing the muscle strips in a dry ice-
acetone slurry and then crushing the tissue with mor-
tar and pestle under liquid N2. The powder was re-
suspended in homogenization bu¡er (20 mM HEPES
pH 7.4, 20 mM sucrose, 100 mM NaF, 15 mM
EDTA, 2 mM EGTA, 1 mM PMSF, and 1.3%
SDS) and boiled for 5 min.
Two-dimensional gel electrophoresis was per-
formed using vertical slab isoelectric focusing gels
with the modi¢cation described by Hochstrasser et
al. [16]. The conditions were optimized to emphasize
the low molecular weight phosphoproteins (in the
range of MLC20). Brie£y, the samples were ace-
tone-precipitated and reconstituted in 9 M urea and
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2% CHAPS. The protein concentrations of the sam-
ples were determined and 150 Wg of protein were
adjusted to a ¢nal concentration of 9 M urea, 2%
CHAPS, 100 mM dithiothreitol (DTT), 15% glycer-
ol, and 5% ampholines (5 parts 6^8, 3 parts 5^7,
2 parts 3^10). The ¢rst dimensions were focused for
10 000 Vh, and then run on a 12% SDS-PAGE sec-
ond dimension [17]. The gels were stained with Coo-
massie brilliant blue, dried, and exposed to Kodak
XAR ¢lm.
For immunoblotting, second dimension PAGE
gels were transferred to Immobilon-P (Millipore,
Bedford, MA), blocked with TBS-milk (10 mM
Tris (pH 7.4), 150 mM NaCl, 5% milk), washed
with TBS-Tween (10 mM Tris (pH 7.4), 150 mM
NaCl, 0.5% Tween 20), and probed with mouse
anti-HSP27 antibody (1:5000 in TBS-milk for 1 h).
Immunoreactive proteins were detected using per-
oxidase conjugated goat anti-mouse (1:2000 in block
bu¡er) and Western blot chemiluminescence reagent
(DuPont-NEN, Boston, MA).
2.4. MLC20 phosphorylation
Strips of bovine renal artery smooth muscle were
equilibrated in a muscle bath as described above. The
strips were kept in bu¡er (control) or stimulated with
KCl (110 mM) or CSA (0.4 mM). When a maximal
contractile response was obtained (after 10 min), the
muscles were immediately snap frozen with liquid N2
cooled tongs and ground to a ¢ne powder under
liquid N2. The powder was placed in 90% acetone,
10% trichloroacetic acid, 10 mM DTT and subse-
quently washed 3 times with 100% acetone, 10 mM
DTT. The pellet was resuspended in 9 M urea, 2%
CHAPS, 100 mM DTT and protein concentrations
determined. Twenty Wg of protein was separated on
glycerol-urea mini-gels (40% glycerol, 15% acryl-
amide, 0.75% bisacrylamide, 10 mM Tris, and 22
mM glycine) at 150 V for 19 h in the cold room
[18]. The proteins were then transferred to Immobi-
lon (Millipore, Bedford, MA), 100 V for 1 h. The
blots were blocked with TBS-milk and then incu-
bated overnight with anti-MLC20 antibodies
(1:4000 in TBS-milk). After washing (6 times with
TBS-Tween), the blots were incubated in 125I-protein
A and the relative amounts of phosphorylated and
non-phosphorylated MLC20 were quantitated with a
PhosphorImager.
2.5. Statistical analysis
Values are reported as mean þ S.E.M. and n refers
to the number of animals examined. The statistical
di¡erences between groups were determined with one
way repeated measures analysis of variance (AN-
OVA) using Sigma Stat software (Jandel Scienti¢c,
San Rafael, CA). A P value less than 0.05 was con-
sidered signi¢cant. Densitometric analysis of immu-
noreactive HSP27 was performed using a CCD
camera interfaced with a 2D analyzer software pack-
age (Innovision Software, Bioimage, Ann Arbor,
MI). The MLC20 bands and phosphorylated proteins
on two-dimensional gels were quantitated with a
PhosphorImager (Molecular Dynamics, Sunnyvale,
CA) and ImageQuant software (Molecular Dy-
namics).
Fig. 1. CSA-induced contractions of renal artery smooth
muscle. Strips of renal artery smooth muscle were equilibrated
in a muscle bath and after the initial response to high extracel-
lular KCl (110 mM) was determined, the strips were contracted
with CSA (0.4 mM). The CSA was then washed out (W, panel
A), or remained in the bath and sodium nitroprusside (10 WM,
S, panel B), or forskolin (10 WM, F, panel C) was added.
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3. Results
3.1. CSA is a direct vascular smooth muscle
contractile agonist
CSA (0.4 mM) induces contraction in bovine renal
artery smooth muscles which relax when the CSA
was washed out (100% relaxation, n = 6, Fig. 1); or
with the addition of the vasorelaxants, sodium nitro-
prusside (10 WM, 94 þ 3% relaxation, n = 8, Fig. 1);
or forskolin (10 WM, 88 þ 6% relaxation, n = 6, Fig.
1). The dose of CSA used in this study represents the
dose necessary for half-maximal contraction of bo-
vine renal artery smooth muscle [11]. This dose is
higher than optimal serum levels of CSA (250^350
ng/ml); however, it approaches the peak serum con-
centrations (1500^2000 ng/ml) that can occur in clin-
ical settings.
3.2. Phosphorylation events associated with
CSA-induced contractions in renal artery
smooth muscle
Whole cell phosphorylation and two-dimensional
gel electrophoresis of strips of renal artery smooth
muscles treated with CSA (0.4 mM for 10 min) led to
increases in the phosphorylation of speci¢c phospho-
proteins. There were increases in the phosphorylation
of multiple 27 kDa proteins with di¡erent isoelectric
points (Fig. 2, Table 1). Bitar and coworkers have
suggested that phosphorylation of the 27 kDa small
heat shock protein, HSP27, is involved in sustained
Fig. 2. CSA-induced phosphorylation changes in bovine renal artery smooth muscle. Strips of bovine renal artery smooth muscle were
loaded with [32P]orthophosphate and equilibrated in bu¡er (panels A, D, G), treated with cyclosporine A (CSA, 0.4 mM, for 10 min,
panels B, E, H) or treated with cyclosporine A (0.4 mM for 10 min) followed by forskolin (10 WM for 10 min, panels C, F, I). The
strips were homogenized and the proteins separated by isoelectric focusing in the ¢rst dimension (indicated by pI 4.5^6.5) and SDS-
PAGE in the second (the relative mobility of the proteins is indicated by the molecular weight markers on the left of the gels). The
proteins were transferred to Immobilon and the membrane was developed with a PhosphorImager (autoradiographs are depicted in
panels A, B, C). The membranes were then probed with anti-HSP27 antibodies (panels D, E, F) and re-probed with anti-HSP20 anti-
bodies (panels G, H, I). The location of the myosin light chains (M), the isoforms of HSP27 (A, B, C), and the isoforms of HSP20
(Nos. 8, 3, 4, as previously labeled by Takuwa [22]) are indicated on the blots. Non-phosphorylated, immunoreactive HSP20 and
HSP27 are also indicated. These blots are representative of ¢ve separate experiments.
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smooth muscle contraction [18]. To determine
whether the 27 kDa proteins, which demonstrated
an increase in phosphorylation after CSA treatment
were HSP27, two-dimensional gels were transferred
to Immobilon and probed with anti-HSP27 antibod-
ies. Proteins immunoreactive with anti-HSP27 anti-
bodies demonstrated a similar mobility on two-di-
mensional gels as the 27 kDa phosphoproteins (Fig.
2). There was an immunoreactive spot with a relative
mobility of 27 kDa which did not correspond to a
phosphorylated 27 kDa protein. This likely repre-
sents non-phosphorylated HSP27. Densitometric
analysis of the immunoblots demonstrated a signi¢-
cant increase in the amount of the most acidic iso-
form (isoform A) of HSP27 as a fraction of the total
immunoreactive HSP27 after CSA treatment (Fig. 3).
CSA treatment (0.4 mM for 10 min) also led to
increases in the phosphorylation of the MLC20. Pro-
teins from muscles treated with or without CSA (0.4
mM, for 10 min) were separated on glycerol-urea gels
and probed with antibodies against MLC20 [19]. Pro-
teins from muscles treated with high KCl were used
as positive controls. Treatment with CSA led to in-
creases in the phosphorylation of the MLC20 that
Fig. 3. CSA treatment leads to increases in the immunoreactive
isoform of HSP27 in bovine renal artery smooth muscle. Strips
of bovine renal artery smooth muscle were equilibrated as con-
trols (CONT) or treated with CSA (0.4 mM for 10 min) and
the proteins were separated on two-dimensional gels. The pro-
teins were transferred to Immobilon and probed with anti-
HSP27 antibodies. The relative density of the spots was quanti-
tated as described in the speci¢c methods and the fraction of
the immunoreactive acidic isoform of HSP27 (isoform A) ex-
pressed as a percentage of the sum of the total immunoreactive
HSP27 (n = 5, error bars indicate standard error of the mean,
*P6 0.05 ANOVA).
Table 1
Quantitation of phosphorylation changes induced by CSA alone
and CSA followed by forskolin in bovine renal artery smooth
muscle
Protein CSA CSA/FSK
Reference 1.07 þ 0.08 1.02 þ 0.13
MLC20 2.14 þ 0.65* 0.72 þ 0.27
HSP27A 1.76 þ 0.26* 1.32 þ 0.26
HSP27B 1.78 þ 0.19* 1.29 þ 0.22
HSP27C 1.83 þ 0.21* 1.76 þ 0.51*
HSP20 #4 2.01 þ 0.14* 2.26 þ 0.53*
HSP20 #3 1.35 þ 0.21 2.40 þ 0.33*
HSP20 #8 2.06 þ 0.90* 5.40 þ 0.60*
The values are the mean of the fold increase over control þ
S.E.M. for cyclosporine (CSA, 0.4 mM, 10 min) and CSA (0.4
mM, 10 min) followed by forskolin (FSK, 10 WM, 10 min)
treated strips (n = 5, *P6 0.05, ANOVA compared to control).
‘Reference’ refers to the same reference protein identi¢ed by
Takuwa et al. [22]; HSP27A is the isoform of HSP27 with a pI
of 5.5; HSP27B, pI 5.7; HSP27C, pI 5.9; HSP20 #4 is the iso-
form of HSP20 with a pI of 6.0; HSP20 #3, pI 5.9; and
HSP20 #8, pI 5.7.
Fig. 4. CSA treatment leads to increases in the phosphorylation
of MLC20. Strips of bovine renal artery smooth muscle were
equilibrated in a muscle bath and after an initial high KCl con-
traction, remained in bu¡er (CONT), or were treated with high
KCl (110 mM, for 5 min), or CSA (0.4 mM, 10 min). The sam-
ples were separated on glycerol-urea gels [18], and probed with
antibodies against MLC20. A representative blot is depicted in
panel A and the arrow identi¢es the phosphorylated isoform of
MLC20. Densitometric analysis of multiple blots is depicted in
panel B (n = 5 di¡erent strips, error bars depict standard error
of the mean, *P6 0.05, ANOVA).
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were similar to the increases that occurred with high
extracellular KCl (Fig. 4).
Forskolin-induced relaxation of renal artery
smooth muscles that had been pre-contracted with
CSA led to decreases in the phosphorylation of the
MLC20 some isoforms of HSP27 (Table 1). Cyclic
nucleotide-dependent relaxation was associated with
increases in the phosphorylation of three 20 kDa
proteins (Table 1). These proteins have recently
been identi¢ed as di¡erent isoforms of the small
heat shock protein, HSP20 [20]. Proteins immuno-
reactive with anti-HSP20 antibodies demonstrated a
similar mobility on two-dimensional gels as the
20 kDa phosphoproteins (Fig. 2).
4. Discussion
Chronic administration of CSA signi¢cantly and
reproducibly produces hypertension in humans and
animal models [1]. This may be due to a direct e¡ect
of CSA on the vascular smooth muscle [8,11]. In-
creases in the phosphorylation of a number of pro-
teins including the myosin light chains (MLC20), des-
min, caldesmon, and the small heat shock protein,
HSP27, have been associated with the contractile
state of vascular smooth muscles [21^23]. Increases
in the phosphorylation of these proteins may occur
with activation of speci¢c kinases which are capable
of phosphorylating the speci¢c proteins, or inhibition
of the phosphatases which de-phosphorylate these
proteins [24]. CSA is a speci¢c inhibitor of Ca2/
calmodulin-dependent phosphatase (phosphatase 2B
or calcineurin) [12]. Inhibitors of type 1 and 2A
phosphatases have been shown to directly induce
vascular smooth muscle contraction, presumably as
a result of an inhibition of the de-phosphorylation of
speci¢c proteins [13,14]. However, the e¡ect of CSA,
a type 2B phosphatase inhibitor, on protein phos-
phorylation events in vascular smooth muscles has
not been previously examined.
In this investigation we determined that CSA-in-
duced contractions are associated with increases in
the phosphorylation of a set of speci¢c proteins sim-
ilar to those that become phosphorylated during ag-
onist-induced contractions in multiple types of
smooth muscles [21^23]. Stimulation of renal artery
smooth muscle with CSA led to increases in the
phosphorylation of MLC20 (Table 1, Fig. 4). In-
creases in the phosphorylation of the MLC20 are
thought to regulate the initiation of smooth muscle
contraction [25]. However, sustained vascular
smooth muscle contraction has been described in
many systems in which the state of MLC20 phos-
phorylation returns to its baseline value during the
sustained phase of contraction [26]. Thus, numerous
investigators have implicated other phosphorylation
events in mediating the sustained phase of contrac-
tion [27^29].
CSA treatment also led to increases in the phos-
phorylation of the small heat shock protein, HSP27
(Table 1, Figs. 2 and 3). Other investigators have
noted increases in the phosphorylation of 27 kDa
proteins that is temporally associated with smooth
muscle contraction [23]. Increases in the phosphoryl-
ation of HSP27 is also associated with carbachol
stimulated tracheal smooth muscle contraction [30]
and thrombin-induced vascular smooth muscle con-
tractions [31].
Prolonged treatment of animals with CSA leads to
an attenuation of the endothelial-independent relax-
ation response to sodium nitroprusside [10]. In addi-
tion, vascular smooth muscle contractions induced
by the type I/IIa phosphatase inhibitor, calyculin,
are refractory to relaxation with the addition of so-
dium nitroprusside [32]. However, contractions in-
duced by the acute administration of CSA in a
muscle bath relax rapidly with the addition of the
guanylate cyclase activator, sodium nitroprusside or
the adenylate cyclase activator, forskolin (Fig. 1).
Cyclic nucleotide-dependent relaxation of CSA-pre-
contracted renal artery smooth muscles is associated
with decreases in the phosphorylation of the MLC20
and some isoforms of HSP27 (Table 1). Relaxation
was also associated with increases in the phospho-
rylation of two 20 kDa proteins that have recently
been identi¢ed as HSP20 (Fig. 2, Table 1) [20].
Heat shock proteins function as molecular chaper-
ones which confer resistance to cellular stresses.
While the function of HSPs has been well established
in cultured cells, less is known about the actual phys-
iologic functions of HSPs in intact tissues. These
data and the data of others suggest that the small
HSPs may play a role in modulating the contractile
state of smooth muscles. Bitar and co-workers have
recently implicated HSP27 as a mediator of sustained
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rectal sphincter smooth muscle tone [18]. HSP27 has
been shown to be relatively abundant in muscle tis-
sue [33] and recent data suggest that HSP27 interacts
with and regulates the actin cytoskeleton [34^37].
HSP20 was initially identi¢ed as a byproduct of the
puri¢cation of HSP27 and increases in the phospho-
rylation of HSP20 are associated with cyclic nucleo-
tide-dependent relaxation of smooth muscle [20,38].
The small HSPs exist intracellularly as large macro-
molecular aggregates [39^42]. Thus, it is possible that
the oligomeric association of HSP27 and HSP20
functions as a molecular chaperone to stabilize the
contractile machinery resulting in sustained contrac-
tion and that phosphorylation of HSP20 disrupts this
interaction leading to relaxation.
Several phosphatases have been shown to use
phosphorylated MLC20 as a substrate in vitro and
the majority of these phosphatases have been classi-
¢ed as type 1 or 2A. A myosin bound phosphatase
has been identi¢ed that is a trimeric type 1 enzyme
[43]. Increases in the phosphorylation of MLC20 in
vascular smooth muscle treated with CSA suggest
that type 2B phosphatase may also regulate MLC20
phosphorylation. The Ca2/calmodulin-dependent
protein phosphatase (calcineurin) has been impli-
cated in the de-phosphorylation of HSP25, the mur-
ine analogue of bovine and human HSP27 [44]. Since
the activation of many kinases is dependent on phos-
phorylation, it is also possible that the increases in
phosphorylation of speci¢c smooth muscle proteins
associated with CSA treatment are due to an inhib-
ition of the de-phosphorylation of speci¢c kinases
leading to persistent activation of the kinases.
In summary, CSA-induced renal artery smooth
muscle contractions are associated with increases in
the phosphorylation of a similar speci¢c set of pro-
teins as occurs with agonist-induced contraction. One
of these proteins was identi¢ed as the small heat
shock protein, HSP27. Cyclic nucleotide-dependent
relaxation of CSA-induced contractions are associ-
ated with decreases in the phosphorylation of these
regulatory proteins and with increases in the phos-
phorylation of the small heat shock protein, HSP20.
CSA may directly induce vascular smooth muscle
contraction by speci¢cally inhibiting the de-phos-
phorylation of smooth muscle regulatory proteins
or by inhibiting the de-phosphorylation of kinases
thus producing persistent activation of the kinases.
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